Kao, 2014 - Google Patents
HB eAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon?Kao, 2014
View PDF- Document ID
- 10147309507234630746
- Author
- Kao J
- Publication year
- Publication venue
- Liver International
External Links
Snippet
Although chronic hepatitis B (CHB) is a global health threat, it is now a preventable and treatable disease. Seven agents have been approved for the treatment of CHB. Although many patients prefer potent long‐term nucleos (t) ide analogues (NA s) as the first‐line …
- 208000002672 Hepatitis B 0 title abstract description 64
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kao | HB eAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon? | |
| Zoulim | Hepatitis B virus resistance to antiviral drugs: where are we going? | |
| Liaw et al. | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update | |
| Malik et al. | Chronic hepatitis B virus infection: treatment strategies for the next millennium | |
| Pramoolsinsup | Management of viral hepatitis B | |
| Hadziyannis et al. | Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment | |
| Koumbi | Current and future antiviral drug therapies of hepatitis B chronic infection | |
| Papatheodoridis et al. | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection | |
| Santantonio et al. | Chronic hepatitis B: Advances in treatment | |
| Suk‐Fong Lok | Hepatitis B: 50 years after the discovery of Australia antigen | |
| Lo et al. | Current developments in nucleoside/nucleotide analogues for hepatitis B | |
| Hui et al. | Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon | |
| Brunetto et al. | Interferon therapy of chronic hepatitis B | |
| Abu-Amara et al. | Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? | |
| Leung | Recent data on treatment of chronic hepatitis B with nucleos (t) ide analogues | |
| Vlachogiannakos et al. | Optimal therapy of chronic hepatitis B: how do I treat HBeAg‐positive patients? | |
| Chien et al. | Nucleos (t) ide analogues for hepatitis B virus: strategies for long-term success | |
| Liu et al. | Hepatitis B: treatment choice and monitoring for response and resistance | |
| Saikia et al. | Management of patients with HBeAg-negative chronic hepatitis B | |
| Liaw | Management of patients with chronic hepatitis B | |
| Gish | Current treatment and future directions in the management of chronic hepatitis B viral infection | |
| Lai et al. | Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B | |
| Buster et al. | Peginterferon for the treatment of chronic hepatitis B in the era of nucleos (t) ide analogues | |
| Piratvisuth | Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B | |
| Olsen et al. | Hepatitis B treatment: lessons for the nephrologist |